We would like to share some of the latest developments in the industry and provide an outlook of some of our key activities. If you would like to receive this update straight to your inbox, please feel free to sign up to our monthly newsletter.
Industry News
Global Outlook on Affordability of Biotherapeutic Drugs
Congratulations to researchers from the Department of Chemical Engineering, Indian Institute of Technology, Delhi, India and the Welcome Trust, London, UK on their recent publication “Global outlook on affordability of biotherapeutic drugs”.
Here are our key takeaways:
- High molecular weight biologics (many of them antibodies are unaffordable in a large proportion of countries studied.
- When biosimilars enter the market the price decreases and patient access increases.
- The price of biotherapeutics is particularly high in the USA.
- The gap in affordability between the highest and lowest income countries is expected to increase.
- The harmonization of regulatory pathways needs strengthening in LMICs.
News at Just - Evotec Biologics
Biomanufacturing Cost Reduction by 75%
Our latest paper discusses cost reduction efforts. By leveraging intensification, minimization, and simplification in bioprocessing workflows, Just-Evotec Biologics can achieve higher productivity, better resource utilization and lower facility costs. Collectively, these benefits contribute to reducing the COGM of biotherapeutics.
Turning the Crank using a Hybrid Continuous Purification Platform
We recently presented at the Recovery of Biological Products XX conference.
Learn how:
- Process intensification solutions for monoclonal antibodies, Fc-fusion proteins and bispecific antibodies ease liquid handling pain points.
- Our J.CHOTM High Expression System is delivering perfusion permeate titers of over 2 g/L/d over 25 days.
- Continuous capture chromatography significantly enhances resin utilization.
- Two tank virus inactivation steps can be developed with bench-scale models.
Integration of Rapid Bioburden Testing Into Production Quality Management Systems and Process Control
This paper was written as part of a NIIMBL cooperation with alongside authors Irina Ramos (Astra Zeneca), Gene Schaefer (NIIMBL) and Michelle Najera (Just – Evotec Biologics).
Recent Press Releases
Just – Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz
Just – Evotec Biologics expanded its strategic partnership with Sandoz. Just – Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025. This expanded partnership solidifies Just – Evotec Biologics’ commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD® biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France.
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
Just – Evotec Biologics was selected by the DOD to develop an accelerated monoclonal antibody development and manufacturing solution for the DOD’s Manufacturing Optimization Program. The multi-year program award supports the U.S. Government’s effort to enhance its rapid response capabilities for biologics medical countermeasures - MCMs.
